MedTrace Logo

Pharmacokinetics of Imipenem During Ex Vivo Lung Perfusion (EVLP)

NCT02670239 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2016-02-01

No results posted yet for this study

Summary

Ex vivo lung perfusion (EVLP) is an established strategy to evaluate and optimize high-risk donor lungs that would otherwise be rejected for transplantation mainly due to the presence of edema or infection. Extracorporeal circuits may negatively affects pharmacokinetic (PK) of several drugs including antibiotics, thus exposing patients to risk of therapeutic failure or drug toxicity. The investigators set out to examine the concentration of imipenem in lung perfusate and in lung biopsy during EVLP, and its clinical impact.

Conditions

  • Lung Transplantation

Interventions

PROCEDURE

normothermic ex vivo lung perfusion

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02670239 on ClinicalTrials.gov